US2017096471A1PendingUtilityA1

Soluble tumor necrosis factor receptor treatment of medical disorders

65
Assignee: IMMUNEX CORPPriority: Apr 19, 1999Filed: Sep 8, 2016Published: Apr 6, 2017
Est. expiryApr 19, 2019(expired)· nominal 20-yr term from priority
Inventors:Barbara Finck
A61K 39/39533A61K 38/1793A61P 19/02A61K 38/00C07K 2319/30Y10S530/866A61P 17/06A61K 31/519C07K 14/70578
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention pertains to methods and compositions for treating medical disorders characterized by elevated levels or abnormal expression of TNFα by administering a TNFα antagonist, such as recombinant TNFR:Fc.

Claims

exact text as granted — not AI-modified
What is claimed: 
     
         1 . A method for treating a patient having psoriasis comprising administering to the patient a therapeutically effective dose of TNFR:Fc. 
     
     
         2 . The method of  claim 1 , wherein the patient has psoriatic arthritis. 
     
     
         3 . The method of  claim 2 , wherein a dose of 50-100 mg is administered once per week. 
     
     
         4 . The method of  claim 2 , wherein a dose of 25-50 mg is administered twice per week. 
     
     
         5 . The method of  claim 2 , wherein the TNFR:Fc is administered by subcutaneous injection. 
     
     
         6 . The method of  claim 1 , wherein the patient does not have psoriatic arthritis. 
     
     
         7 . The method of  claim 6 , wherein a dose of 50-100 mg is administered once per week. 
     
     
         8 . The method of  claim 6 , wherein a dose of 25-50 mg is administered twice per week. 
     
     
         9 . The method of  claim 6 , wherein the TNFR:Fc is administered by subcutaneous injection. 
     
     
         10 . The method of  claim 1 , wherein the patient has plaque psoriasis. 
     
     
         11 . The method of  claim 10 , wherein the patient has psoriatic arthritis. 
     
     
         12 . The method of  claim 11 , wherein a dose of 50-100 mg is administered once per week. 
     
     
         13 . The method of  claim 11 , wherein a dose of 25-50 mg is administered twice per week. 
     
     
         14 . The method of  claim 11 , wherein the TNFR:Fc is administered by subcutaneous injection. 
     
     
         15 . The method of  claim 10 , wherein the patient does not have psoriatic arthritis. 
     
     
         16 . The method of  claim 15 , wherein a dose of 50-100 mg is administered once per week. 
     
     
         17 . The method of  claim 15 , wherein a dose of 25-50 mg is administered twice per week. 
     
     
         18 . The method of  claim 15 , wherein the TNFR:Fc is administered by subcutaneous injection.

Join the waitlist — get patent alerts

Track US2017096471A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.